CASI Pharmaceuticals - Kewajiban jangka dawa perusahaan CASI

CASI Pharmaceuticals (CASI) is a reputable intermediary providing access to advanced blood cancer treatments for residents of China. The business relies on strict compliance with NMPA regulations, which creates a significant barrier to entry for new players. The licensing model for Western drugs minimizes R&D risks, and the debt load ratio is 0.00. This chart of current share prices on GURU.Markets confirms the holding's market positions.

CASI (CASI Pharmaceuticals) riwayat Utang jangka dawa perusahaan saka 04.07.2022 nganti 14.03.2026

Ringkesan rincian data analitis CASI Pharmaceuticals, Inc. (CASI)

- rega lan prakiraan konsensus rega:

Kurs saham CASI Pharmaceuticals Inc.|CASI - Prakiraan konsensus analis

- data kapitalisasi pasar:

Biji pasar CASI Pharmaceuticals|CASI - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Aset Bersih saben Saham CASI Pharmaceuticals|CASI - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku casipharmaceuticals.com|CASI - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi CASI Pharmaceuticals|CASI - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas CASI Pharmaceuticals Inc.|CASI - Utang perusahaan|Rasio utang marang kapitalisasi buku CASI Pharmaceuticals|CASI - Utang jangka dawa perusahaan|Utang jangka cendhak CASI Pharmaceuticals

Analisis kabeh metrik perusahaan:CASI Pharmaceuticals (CASI)

To select high-quality assets, investors analyze the liability structure to assess capital resilience against long-term risks. This metric captures the total amount of loans with maturities exceeding one year, reflecting the balance between financial security and expansion rates, which is critical for CASI Pharmaceuticals (CASI) when financing costly clinical trials for oncology drugs and developing its R&D pipeline, based on the company's current level of long-term debt.

Pesaing langsung